{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:39Z","timestamp":1794047379679,"version":"4.8.0"},"reference-count":10,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2020.278203","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T05:15:49Z","timestamp":1617254149000},"page":"1226-1227","source":"Crossref","is-referenced-by-count":1,"title":["Comment on \u201cCombining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON\/LLPC Transplant BRaVE study.\u201d"],"prefix":"10.3324","volume":"106","author":[{"given":"Marco","family":"Picardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"24585","doi-asserted-by":"crossref","unstructured":"Younes A, Bartlett NL, Leonard JP. Brentuximab vedotin (SGN- 35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010; 363(19):1812-1821.","DOI":"10.1056\/NEJMoa1002965"},{"key":"24586","doi-asserted-by":"crossref","unstructured":"Connors JM. Hodgkin lymphoma: outsmarting HRS cells. Blood. 2020; 136(21):2362-2364.","DOI":"10.1182\/blood.2020008250"},{"key":"24587","doi-asserted-by":"crossref","unstructured":"Kersten MJ, Driessen J, Zijlstra JM. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON\/LLPC Transplant BRaVE study. Haematologica. 2020.","DOI":"10.3324\/haematol.2019.243238"},{"key":"24588","doi-asserted-by":"crossref","unstructured":"Moskowitz AJ, Schr\u00f6der H, Yahalom J. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosfamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single- centre, phase 2 study. Lancet Oncol. 2015; 16(3):284-292.","DOI":"10.1016\/S1470-2045(15)70013-6"},{"key":"24589","doi-asserted-by":"crossref","unstructured":"LaCasce AS, Bociek RG, Sawas A. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018; 132(1):40-48.","DOI":"10.1182\/blood-2017-11-815183"},{"key":"24590","doi-asserted-by":"crossref","unstructured":"Garcia-Sanz R, Sureda A, de la Cruz F. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Ann Oncol. 2019; 30(4):612-620.","DOI":"10.1093\/annonc\/mdz009"},{"key":"24591","doi-asserted-by":"crossref","unstructured":"Cohen JB, Wei L, Maddocks KJ. Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent\/ refractory Hodgkin lymphoma: results of a phase 1\/2 study. Cancer. 2020; 126(6):1235-1242.","DOI":"10.1002\/cncr.32640"},{"key":"24592","doi-asserted-by":"crossref","unstructured":"De Filippi R, Cillo M, Crisci S. Continuous exposure to bendamustine (BDM) results in stable upregulation of CD30 and increased sensitivity to brentuximab vedotin (BV) in tumor cells of Hodgkin lymphoma (HL). Blood. 2015; 126(23):2479.","DOI":"10.1182\/blood.V126.23.2479.2479"},{"key":"24593","doi-asserted-by":"crossref","unstructured":"Picardi M, Della Pepa R, Giordano C. Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma. Blood Adv. 2019; 3(9):1546-1552.","DOI":"10.1182\/bloodadvances.2019000123"},{"key":"24594","unstructured":"Della Pepa R, Picardi M, Pugliese N. Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma: mature results of a monocentric prospective trial. Haematologica. 2020; 105(s2):S101-102."}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/10223\/73221","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10223\/73223","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10223\/73221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:59:20Z","timestamp":1794045560000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/10223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":10,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2020.278203","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,1]]}}}